[go: up one dir, main page]

WO2000065030A3 - Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites - Google Patents

Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites Download PDF

Info

Publication number
WO2000065030A3
WO2000065030A3 PCT/CA2000/000482 CA0000482W WO0065030A3 WO 2000065030 A3 WO2000065030 A3 WO 2000065030A3 CA 0000482 W CA0000482 W CA 0000482W WO 0065030 A3 WO0065030 A3 WO 0065030A3
Authority
WO
WIPO (PCT)
Prior art keywords
undesired
removal
cells
coli
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/000482
Other languages
French (fr)
Other versions
WO2000065030A2 (en
Inventor
Satya Prakash
Thomas M S Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to AU42814/00A priority Critical patent/AU4281400A/en
Publication of WO2000065030A2 publication Critical patent/WO2000065030A2/en
Publication of WO2000065030A3 publication Critical patent/WO2000065030A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a composition for the removal of at least one undesired electrolyte and/or metabolite in a patient, which comprises a genetically engineered E. coli DH5 cells microencapsulated in artificial cells to be capable of removing said undesired electrolyte and/or metabolite, wherein said undesired electrolyte is selected from the group consisting of K, Mg, P, Na, Cl and said undesired metabolite is selected from the group consisting of uric acid, cholesterol, bilirubin, and creatinine, wherein said removal of undesired electrolyte and/or metabolite lowers the undesired chemical concentration to a therapeutically acceptable level.
PCT/CA2000/000482 1999-04-28 2000-04-27 Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites Ceased WO2000065030A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42814/00A AU4281400A (en) 1999-04-28 2000-04-27 Artificial cells microencapsulated genetically engineered (e. coli dh 5) cells for the removal of undesired electrolytes and/or metabolites

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13146899P 1999-04-28 1999-04-28
US60/131,468 1999-04-28

Publications (2)

Publication Number Publication Date
WO2000065030A2 WO2000065030A2 (en) 2000-11-02
WO2000065030A3 true WO2000065030A3 (en) 2001-01-25

Family

ID=22449591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000482 Ceased WO2000065030A2 (en) 1999-04-28 2000-04-27 Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites

Country Status (2)

Country Link
AU (1) AU4281400A (en)
WO (1) WO2000065030A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649447B2 (en) 2017-06-12 2023-05-16 Duke University Compositions, systems, and methods for the production of biomolecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024196A1 (en) * 1990-06-13 1991-12-14 Thomas M. S. Chang Porous microbead permeable to macromolecules having immobilized therein at least one biological particulate
EP0475542A1 (en) * 1990-08-24 1992-03-18 Preussag Noell Wassertechnik GmbH Process and apparatus for removing heavy metals from aqueous media by means of a bioadsorber
US5567451A (en) * 1991-02-25 1996-10-22 Champagne Moet & Chandon Alginate or pectate gel deficient in gelling ions for use in binding metal ions
WO1997026903A1 (en) * 1996-01-23 1997-07-31 Mcgill University Microencapsulated genetically engineered microorganisms for clinical application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024196A1 (en) * 1990-06-13 1991-12-14 Thomas M. S. Chang Porous microbead permeable to macromolecules having immobilized therein at least one biological particulate
EP0475542A1 (en) * 1990-08-24 1992-03-18 Preussag Noell Wassertechnik GmbH Process and apparatus for removing heavy metals from aqueous media by means of a bioadsorber
US5567451A (en) * 1991-02-25 1996-10-22 Champagne Moet & Chandon Alginate or pectate gel deficient in gelling ions for use in binding metal ions
WO1997026903A1 (en) * 1996-01-23 1997-07-31 Mcgill University Microencapsulated genetically engineered microorganisms for clinical application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: "Therapeutic uses of microencapsulated genetically engineered cells", MOLECULAR MEDICINE TODAY, vol. 4, May 1998 (1998-05-01), pages 221 - 227, XP000957917 *
PRAKASH ET AL.: "Artificial cell microcapsules containing genetically engineered E. coli DH5 cells for in-vitro lowering of plasma potassium, phosphate, magnesium, sodium, chloride, uric acid, cholesterol, and cratinine: A preliminary report", ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, vol. 27, September 1999 (1999-09-01), pages 475 - 481, XP000961328 *
PRAKASH ET AL.: "Genetically engineered E. coli cells containing K. aerogenes gene, microencapsulated in artificial cells for urea and ammonia removal", BIOMATERIALS ARTIFICIAL CELLS AND IMMOBILIZATION BIOTECHNOLOGY, vol. 21, no. 5, 1993, pages 629 - 636, XP000961360 *

Also Published As

Publication number Publication date
AU4281400A (en) 2000-11-10
WO2000065030A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
AU2002241654A1 (en) Lithium anodes for electrochemical cells
AU2002312067A1 (en) Lithium anodes for electrochemical cells
AU1796701A (en) Lithium anodes for electrochemical cells
WO1999035255A3 (en) Compositions and methods for regulated secretion from neuroendocrine cell lines
CN102608176B (en) Method that is solution-stabilized with divalent manganesetion or that be re-activated creatinine sensor
WO2003005479A1 (en) Non-aqueous electrolyte cell, electrolyte stabilizing agent, and phosphazene derivative and method for preparation thereof
EP1722431A3 (en) Secondary battery using a radical compound as active electrode material
EP2277829A3 (en) Methods of making lithium metal compounds useful as cathode active materials
AU7587100A (en) Method of making multi-layer electrochemical cell devices
AU8567898A (en) Electrochemical methods for recovery of ascorbic acid
AU1796601A (en) Methods of preparing electrochemical cells
DE69501450D1 (en) Compensation of lithium / (silver vanadium) oxide cells (LI / SVO)
AU2002252897A1 (en) Metal-supported solid electrolyte electrochemical cell and multi cell reactors incorporating same
AU2001247638A1 (en) Flat, bonded-electrode rechargeable electrochemical cell and method of making same
DE60001377D1 (en) Positive electrode, process for its manufacture and lithium battery using the same
WO2002067956A3 (en) Method for purifying a biological composition
AU3601099A (en) Method of making polymer electrolyte electrochemical cells
WO2003099281A3 (en) Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
ATE342334T1 (en) CONTROLLED RELEASE COVERED PEROXYGEN COMPOUNDS, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
AU1796501A (en) Methods of preparing electrochemical cells
WO1999015179A8 (en) Methods of limiting apoptosis of cells
WO2000065030A3 (en) Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites
AU2001256357A1 (en) Method comprising the indirect electrochemical regeneration of nad(p)h
AU2001277192A1 (en) Gelled anode or electrolyte solution for an electrochemical cell
WO2002058488A3 (en) Composition containing creatine and phosphorus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10031640

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)